Blueprint Medicines Corp
F:2L9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Blueprint Medicines Corp
F:2L9
|
US |
|
F
|
Fancy Wood Industries PCL
SET:FANCY
|
TH |
|
S
|
SCI Electric PCL
SET:SCI
|
TH |
|
J
|
Juventus FC SpA
PSE:JUVE
|
IT |
|
NanoViricides Inc
F:NV3P
|
US |
|
T
|
Thai OPP PCL
SET:TOPP
|
TH |
|
R
|
Right Tunnelling PCL
SET:RT
|
TH |
|
Moncler SpA
OTC:MONRF
|
IT |
Intrinsic Value
Is 2L9 undervalued or overvalued?
See the intrinsic value estimate for Blueprint Medicines Corp and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
2L9 looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with 2L9’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Blueprint Medicines Does
In the demanding world of biotechnology, Blueprint Medicines Corp stands out as an influential player, steering the course of precision therapy through innovation. Founded by a team of forward-thinking scientists, the company is deeply entrenched in the pursuit of novel treatments targeting rare genetic diseases and cancers driven by specific genomic alterations. Leveraging its proprietary compound library and a research-centric approach, Blueprint Medicines develops small-molecule kinase inhibitors designed to selectively modulate growth and survival signals in cells.
- Headquarters
- United States of America US
- Employees
- 495
- IPO date
- Apr 30, 2015
Revenue & Expenses Breakdown
Blueprint Medicines Corp
Earnings Waterfall
Blueprint Medicines Corp
The intrinsic value for Blueprint Medicines Corp (2L9) under the Base Case is hidden EUR.
Compared with the current market price of 110.05 EUR, the stock appears hidden.